-transparent.png){kind=logo}
Because of the importance of homocysteine thiolactone metabolism in the growth of normal tissues, and because of abnormal metabolism of homocysteine thiolactone in malignant cells, N-substituted derivatives of homocysteine thiolactone were synthesized and assayed for antineoplastic and anticarcinogenic activities. A single dose of 2.5 mg/kg of the synthetic derivative, N-homocysteine thiolactonyl retinamido cobalamin, injected directly into subcutaneous human pancreatic adenocarcinoma neoplasms in athymic mice, caused 50% inhibition of growth without evidence of toxicity. The findings suggest a novel approach to counteracting the growth of malignant neoplasms and support the hypothesis of a deficiency of an N-homocysteine thiolactonyl derivative in malignant cells.
K S McCully, and
G N Tzanakakis, and
M P Vezeridis
September 1989,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
K S McCully, and
G N Tzanakakis, and
M P Vezeridis
June 1987,
Research communications in chemical pathology and pharmacology,
K S McCully, and
G N Tzanakakis, and
M P Vezeridis
October 1987,
Carcinogenesis,
K S McCully, and
G N Tzanakakis, and
M P Vezeridis
August 1990,
Atherosclerosis,
K S McCully, and
G N Tzanakakis, and
M P Vezeridis
September 1968,
Proceedings of the National Academy of Sciences of the United States of America,
K S McCully, and
G N Tzanakakis, and
M P Vezeridis
May 2009,
Nutrition reviews,
K S McCully, and
G N Tzanakakis, and
M P Vezeridis
April 1991,
The Journal of clinical investigation,
K S McCully, and
G N Tzanakakis, and
M P Vezeridis
January 2003,
Hematology. American Society of Hematology. Education Program,
K S McCully, and
G N Tzanakakis, and
M P Vezeridis
December 1994,
Journal of medicinal chemistry,
K S McCully, and
G N Tzanakakis, and
M P Vezeridis
August 2005,
Blood,
